Related by context. All words. (Click for frequent words.) 78 advanced NSCLC 78 metastatic colorectal cancer 77 cell lung cancer 74 metastatic renal cell carcinoma 73 renal cell carcinoma 71 metastatic breast cancer 71 hormone refractory prostate cancer 71 HRPC 70 HER2 positive breast cancer 70 metastatic melanoma 70 solid tumors 70 metastatic RCC 69 brain metastases 69 IV NSCLC 69 HER2 positive 68 metastatic 68 metastatic disease 68 CLL 68 castration resistant prostate cancer 68 DLBCL 68 HER2 positive metastatic breast 67 mCRC 67 erlotinib 67 pancreatic adenocarcinoma 67 mRCC 67 metastatic prostate cancer 67 mCRC patients 67 unresectable 67 malignant pleural mesothelioma 67 heavily pretreated 67 nonsmall cell lung cancer 67 liver metastases 67 gefitinib 67 recurrent NSCLC 66 gastric cancer 66 refractory multiple myeloma 66 platinum refractory 66 stage IIIB 66 follicular lymphoma 66 gemcitabine 66 hepatocellular carcinoma HCC 66 chronic lymphocytic leukemia CLL 66 chemotherapy regimens 66 hepatocellular carcinoma 66 colorectal cancer 66 EGFR mutation 65 adjuvant therapy 65 medullary thyroid cancer 65 prostate cancer CRPC 65 cetuximab 65 malignancies 65 pancreatic carcinoma 65 docetaxel 65 sunitinib 65 hepatocellular cancer 65 SCCHN 64 unresectable stage 64 glioblastoma 64 hematologic malignancies 64 metastatic cancer 64 acute myelogenous leukemia AML 64 EGFR mutations 64 recurrent GBM 64 carcinoma 64 axitinib 64 sorafenib 64 neuroendocrine tumors 64 adjuvant chemotherapy 64 Amrubicin 64 lymphoma CTCL 64 resistant ovarian cancer 64 multiple myeloma MM 64 carboplatin paclitaxel 64 IV melanoma 64 IV metastatic melanoma 63 multiple myeloma 63 acute myeloid leukemia AML 63 B CLL 63 neoadjuvant chemotherapy 63 dasatinib 63 prostate cancers 63 indolent NHL 63 soft tissue sarcomas 63 relapsed ovarian cancer 63 adenocarcinoma 63 soft tissue sarcoma 63 vandetanib 63 pancreatic cancers 63 Cell Lung Cancer 63 histologies 63 vinorelbine 63 bortezomib 63 glufosfamide 63 metastatic renal cell 63 leukemia AML 63 HGS ETR1 62 androgen independent 62 heavily pretreated patients 62 metastatic pancreatic cancer 62 lung tumors 62 Vectibix 62 stage IIIB IV 62 metastatic lung cancer 62 EGFR mutation positive 62 carcinoid tumors 62 locoregional 62 relapsed refractory multiple myeloma 62 bevacizumab 62 trastuzumab 62 colorectal cancers 62 resectable 62 hormone receptor positive 62 pancreatic NET 62 HNSCC 62 ASA# 62 IMGN# 62 bendamustine 62 metastatic malignant melanoma 62 distant metastasis 62 gastrointestinal stromal tumors 62 lung cancers 62 prostate cancer AIPC 62 metastatic colorectal 62 relapsed refractory 62 cutaneous T cell 62 CTCL 62 basal cell carcinoma BCC 62 cell lymphoma CTCL 62 epithelial ovarian cancer 62 gefitinib Iressa 61 phase IIb clinical 61 gastrointestinal stromal tumor GIST 61 capecitabine 61 pemetrexed 61 metastatic HRPC 61 KRAS status 61 trabectedin 61 superficial bladder cancer 61 KRAS wild 61 refractory CTCL 61 metastatic CRC 61 cancer mCRC 61 metastases 61 temsirolimus 61 perifosine 61 neoadjuvant therapy 61 lupus nephritis 61 non squamous 61 non squamous NSCLC 61 HER2 + 61 refractory CLL 61 breast cancers 61 rituximab 61 OncoVEX GM CSF 61 FOLFIRI 61 differentiated thyroid 61 castrate resistant prostate cancer 61 evaluable patients 61 HER2 negative 61 docetaxel chemotherapy 61 KRAS mutations 61 Taxotere ® 61 chemoradiation 61 lymphomas 61 squamous histology 61 colorectal cancer CRC 61 glioblastoma multiforme GBM 61 Hepatocellular Carcinoma HCC 61 pomalidomide 61 metastatic colon cancer 61 refractory NSCLC 61 recurrent glioblastoma multiforme 61 seminoma 61 tyrosine kinase inhibitors 61 tumors 61 cancers 61 bladder cancers 61 advanced hepatocellular carcinoma 61 cisplatin 60 pegylated liposomal doxorubicin 60 T#I mutation 60 bone metastasis 60 prostate cancer CaP 60 medically inoperable 60 carboplatin 60 refractory metastatic colorectal cancer 60 imatinib resistant 60 recurrent ovarian cancer 60 disease progression 60 standard chemotherapy regimens 60 metastatic gastric 60 recurrent colorectal cancer 60 relapsed SCLC 60 chlorambucil 60 breast carcinoma 60 glioblastomas 60 cell carcinoma 60 metastatic hormone refractory 60 ipilimumab 60 ovarian cancers 60 neoplasia 60 KRAS mutation 60 Metastatic Colorectal Cancer 60 FOLFOX 60 GIST 60 PXD# 60 invasive bladder 60 temozolomide 60 leukemia CLL 60 figitumumab 60 relapsed multiple myeloma 60 gastric cancers 60 stage IIIb IV 60 PCa 60 elacytarabine 60 decitabine 60 systemic ALCL 60 castrate resistant 60 chemoradiotherapy 60 receptor tyrosine kinase inhibitor 60 refractory AML 60 adenocarcinomas 60 metastatic CRPC 60 EGFR 60 xenograft models 60 melanoma 60 chemoresistant 60 dacarbazine 60 Gefitinib 60 Renal Cell Carcinoma RCC 60 sorafenib Nexavar 60 chronic myeloid leukemia CML 60 DMARD 60 localized prostate cancer 60 Acute Myeloid Leukemia AML 60 AP# [003] 60 operable breast cancer 60 carcinomas 59 neoadjuvant 59 prostate cancer HRPC 59 evaluable 59 clinically localized prostate 59 imatinib Gleevec 59 XL# [003] 59 ovarian carcinoma 59 CaP 59 anti leukemic 59 HCV infected 59 papillary renal cell carcinoma 59 olaparib 59 tumors GIST 59 relapsing remitting multiple sclerosis 59 Gleevec resistant 59 GISTs 59 myelodysplastic syndrome MDS 59 K ras 59 BRAF mutation 59 HCV infection 59 biliary tract cancer 59 recurrent glioblastoma 59 paclitaxel carboplatin 59 metastatic NSCLC 59 hematological cancers 59 adjuvant radiation 59 unresectable locally advanced 59 adecatumumab 59 OPAXIO 59 imatinib 59 pancreatic neuroendocrine tumors 59 CLL SLL 59 metastatic GIST 59 KRAS mutations occur 59 follicular NHL 59 IV malignant melanoma 59 amrubicin 59 metastatic castration resistant 59 irinotecan chemotherapy 59 EGFR tyrosine kinase inhibitors 59 MAGE A3 59 chemotherapy regimen 59 EGFR TKI 59 IMC A# 59 breast tumors 59 EpCAM 59 HER2 positive cancers 59 nab paclitaxel 59 lung metastases 59 taxane therapy 59 EGFR expressing 59 BCIRG 59 mapatumumab 59 nonmetastatic 59 cilengitide 59 tumor recurrence 59 gemcitabine carboplatin 59 anthracyclines 59 Metastatic 59 gastrointestinal stromal tumors GIST 59 T#I [002] 59 distant metastases 59 SUTENT 59 Pemetrexed 59 fluoropyrimidine 59 tumor shrinkage 59 depsipeptide 59 irinotecan 59 metastatic bladder 59 CYT# potent vascular disrupting 59 enzastaurin 59 Doxil ® 59 carfilzomib 59 Erlotinib 59 Genasense ® 59 randomized Phase 59 remission induction 59 T DM1 59 metastatic carcinoma 58 cytotoxic chemotherapy 58 hematological malignancies 58 XELOX 58 registrational trial 58 HCV 58 prostate carcinoma 58 sapacitabine 58 tesmilifene 58 imatinib Gleevec ® 58 alvespimycin 58 dasatinib Sprycel 58 neoadjuvant treatment 58 afatinib 58 gemcitabine chemotherapy 58 IRESSA 58 grade gliomas 58 myelofibrosis 58 ErbB2 positive 58 belinostat 58 Epratuzumab 58 Genasense 58 Fludara 58 fallopian tube carcinoma 58 fludarabine 58 LUX Lung 58 lung adenocarcinoma 58 Metastatic breast cancer 58 lymph node metastases 58 FLT3 58 colorectal liver metastases 58 EGFR HER2 58 prior chemotherapy regimens 58 EGFr 58 Tarceva erlotinib 58 tumor progression 58 androgen deprivation 58 metastatic castrate resistant 58 myeloproliferative diseases 58 HER2 overexpression 58 mutated KRAS 58 K ras mutations 58 breast carcinomas 58 panobinostat 58 KRAS mutant tumors 58 sorafenib Nexavar ® 58 prostate cancer PCa 58 seliciclib 58 Torisel 58 prostate cancer mCRPC 58 anti TNF 58 pheochromocytoma 58 Halaven 58 myelodysplastic syndromes MDS 58 Carcinoma 58 imatinib therapy 58 squamous cell carcinoma SCC 58 obatoclax 58 dasatinib Sprycel ® 58 idiopathic pulmonary fibrosis IPF 58 bevacizumab Avastin ® 58 diabetic nephropathy 58 EGFR inhibitors 58 adjuvant radiotherapy 58 Follicular Lymphoma 58 bone metastases 58 renal tumors 58 cytotoxic therapy 58 Adjuvant chemotherapy 58 abiraterone acetate 58 BR.# 58 AML 58 ZACTIMA 58 BRIM2 58 monotherapy 57 cediranib 57 bevacizumab Avastin 57 HCV SPRINT 57 plus gemcitabine 57 HCV genotype 57 carcinoid 57 patients evaluable 57 histone deacetylase HDAC inhibitor 57 serous ovarian cancer 57 Myelofibrosis 57 TEMODAL 57 symptomatic BPH 57 complete remissions 57 ovarian cancer 57 lymphoid malignancies 57 PROSTVAC ® 57 panitumumab 57 cell lymphomas 57 mutated KRAS gene 57 acute ischemic stroke 57 epithelial tumors 57 Cloretazine 57 taxane 57 vismodegib 57 preoperative chemotherapy 57 Cutaneous T 57 biologic therapy 57 Targretin 57 low dose cytarabine 57 Cloretazine ® 57 antitumor activity 57 colorectal carcinoma 57 renal carcinoma 57 Ozarelix 57 CRPC 57 completely resected 57 PROVENGE 57 docetaxel Taxotere R 57 peritoneal carcinomatosis 57 stage IIIb 57 Multiple Myeloma 57 FOLFOX4 57 Perifosine 57 invasive breast cancer 57 taxanes 57 CHOP chemotherapy 57 tamibarotene 57 resected pancreatic cancer 57 Myelodysplastic Syndrome MDS 57 Aflibercept 57 aflibercept 57 dose cohorts 57 follicular lymphoma FL 57 metastatic breast 57 squamous cell carcinoma 57 HER2 57 Mantle Cell Lymphoma 57 erlotinib Tarceva ® 57 free survival PFS 57 lymphoproliferative disorders 57 antiangiogenic therapy 57 cytogenetic responses 57 systemic lupus erythematosus 57 endometrial cancers 57 Velcade bortezomib 57 Nexavar sorafenib 57 Imprime PGG 57 lintuzumab 57 advanced unresectable 57 metastatic cancers 57 systemic lupus erythematosus SLE 57 relapsed GBM 57 recurrent metastatic 57 Cell Lymphoma 57 cetuximab Erbitux 57 FOLFOX chemotherapy 57 ganetespib 57 pleural mesothelioma 57 HCV genotype 1 57 HuMax CD4 57 HGPIN 57 PROSTVAC TM 57 panitumumab Vectibix 57 IIIB NSCLC 57 Her2 57 AEG# 57 relapsed MM 57 refractory metastatic 57 colon carcinoma 57 acute leukemias 57 assessing T DM1 57 5-FU/LV 57 EGFR expressing mCRC 57 Irinotecan 57 chronic HCV 57 neuroendocrine cancers 57 TORISEL 57 Bezielle 57 HBeAg negative 57 cisplatin chemotherapy 57 Phase Ib II 57 small lymphocytic lymphoma 57 Diffuse Large B 57 alkylating agent 57 tivozanib 57 hepatitis C HCV 57 topotecan 57 Tamibarotene 57 cutaneous melanoma 57 cutaneous T 57 metastatic kidney 57 Bortezomib 57 Proxinium TM 57 allogeneic stem cell 57 leukemia APL 57 refractory Hodgkin lymphoma 57 myelofibrosis polycythemia vera 57 Allovectin 7 ® 57 diagnosed multiple myeloma 57 Stage IIIb 56 taxane chemotherapy 56 posaconazole 56 eribulin mesylate 56 Phase #/#a trial 56 refractory colorectal cancer 56 GvHD 56 iniparib BSI 56 YONDELIS 56 lymph node involvement 56 Xanafide 56 grade glioma 56 adjuvant tamoxifen 56 advanced metastatic renal 56 azacitidine 56 HGS ETR2 56 rheumatoid arthritis RA 56 recurrent malignant glioma 56 cervical carcinoma 56 Chronic lymphocytic leukemia 56 Apaziquone 56 GnRH agonists 56 pertuzumab 56 MAGE A3 ASCI 56 pan HDAC inhibitor 56 myeloproliferative disorders 56 histologically confirmed 56 lymphocytosis 56 palifosfamide 56 chronic myelogenous leukemia CML 56 underwent resection 56 voreloxin 56 refractory acute myeloid 56 lapatinib 56 hepatic metastases 56 Chronic Lymphocytic Leukemia 56 achieve sustained virologic 56 ixabepilone 56 castration resistant 56 Hodgkin lymphoma NHL 56 prognostic variables 56 Hodgkin lymphoma HL 56 refractory PTCL 56 mycophenolate mofetil 56 relapsed CLL 56 mTOR inhibitors 56 stage IIIA 56 Afatinib 56 Glioblastoma Multiforme 56 lumiliximab 56 refractory indolent non 56 aflibercept VEGF Trap 56 imetelstat 56 Toxicities 56 Pixantrone 56 lymphadenectomy 56 nonsquamous histology 56 urothelial carcinoma 56 CR# vcMMAE 56 galiximab 56 histological subtypes 56 Tarceva 56 peritoneal cancer 56 nilotinib 56 ELACYT 56 thymoma 56 Waldenstrom macroglobulinemia 56 Alemtuzumab 56 Chronic Myeloid Leukemia 56 RRMS patients 56 oxaliplatin 56 zalutumumab 56 biochemical recurrence 56 talabostat 56 trastuzumab Herceptin R 56 radiation sensitizer 56 Xcytrin 56 hypomethylating agents 56 BRIM3 56 KRAS 56 relapsed AML 56 Ceflatonin 56 lymphoma subtypes 56 follicular lymphomas 56 vemurafenib 56 sipuleucel T 56 papillary RCC 56 Glufosfamide 56 Renal cell carcinoma 56 SCH # 56 colorectal 56 BCG refractory 56 histological subtype 56 Allovectin 7 56 FOLOTYN 56 chemotherapeutic agent 56 Chronic Lymphocytic Leukemia CLL 56 Surgical resection 56 adverse cytogenetics 56 squamous cell lung cancer 56 GVAX 56 non Hodgkin lymphomas 56 ofatumumab 56 mycosis fungoides 56 FOLFIRI alone 56 sunitinib malate 56 MGd 56 peginterferon 56 squamous 56 alkylating agents 56 ADVEXIN 56 Folfox 56 IGF 1R 56 AQ4N 56 anti EGFR antibody 56 sarcomas 56 Follicular lymphoma 56 mg/m2 dose 56 localized renal 56 Vidofludimus 56 Amigal 56 prostate adenocarcinoma 56 mucinous 56 leukemia ALL 56 BRAF inhibitor 56 epithelial ovarian 56 paclitaxel 56 plus dexamethasone 56 Acute myeloid leukemia 56 IIIA NSCLC 56 Non Hodgkin lymphoma 56 Castration Resistant Prostate Cancer 56 estramustine 56 evaluating REVLIMID 56 chemotherapeutic regimens 56 aHUS 56 Glioblastoma 56 p# biomarker 56 TRISENOX 56 epidermal growth 56 myelodysplastic syndromes 56 forodesine 56 ISEL 56 nilotinib Tasigna ® 56 XYOTAX 56 TREANDA 56 Avastin bevacizumab 56 anti angiogenic therapy 56 follicular non 56 gemcitabine Gemzar 56 docetaxel Taxotere ® 56 relapsing remitting 56 EOquin TM 56 osteosarcomas 56 CMV disease 56 Neoadjuvant 56 FTY# 56 tumor xenograft models 56 activating mutations 55 ponatinib 55 surrogate endpoint 55 Dacogen injection 55 PSMA ADC 55 trastuzumab Herceptin ® 55 melanomas 55 factor receptor 55 tanespimycin 55 pazopanib 55 Gemcitabine 55 estrogen receptor ER 55 HDACi 55 PEGylated interferon beta 1a 55 metachronous 55 metastatic malignant 55 IFN α 55 dacarbazine DTIC 55 HGS# 55 viral kinetics 55 Aplidin 55 trabedersen 55 papillary 55 dacarbazine chemotherapy 55 hormonal therapy 55 liposomal doxorubicin 55 LHRH receptor positive 55 non metastatic osteosarcoma 55 TKI therapy 55 ADXS# 55 unresectable Stage III 55 MDV# 55 BAY #-# 55 malignant neoplasms 55 Clolar 55 tesetaxel 55 Hepatocellular Carcinoma 55 ccRCC 55 Xeloda 55 severe sepsis 55 squamous cell 55 Acute Myelogenous Leukemia AML 55 predictive biomarker 55 chemotherapeutic agents 55 curative resection 55 Virulizin ® 55 Carboplatin 55 NSCL cancer 55 BRCA deficient 55 Afinitor 55 TKIs 55 vinca alkaloid 55 SJIA 55 refractory prostate cancer 55 phase Ib 55 AVOREN 55 pT2 55 Multiple Myeloma MM 55 DMARDs 55 COU AA 55 refractory ovarian cancer 55 KRAS mutant 55 evaluating T DM1 55 urothelial bladder cancer 55 endocrine therapy 55 ERBITUX 55 IMA# 55 situ CIS 55 Advexin 55 randomized Phase III 55 FOLFOX6 55 INCB# [001] 55 nasopharyngeal carcinoma 55 malignancy 55 underwent surgical resection 55 cetuximab Erbitux R 55 iniparib 55 factor receptor EGFR 55 CRp 55 Acute Myeloid Leukemia 55 relapsing multiple sclerosis 55 hormone refractory 55 tyrosine kinase inhibitor 55 HSCT 55 metastatic lesions 55 hepatitis C genotype 55 Pralatrexate 55 Iressa 55 interferon alfa 55 Squamous 55 squamous cell histology 55 SWOG 55 lenalidomide Revlimid R 55 candidemia 55 NSCLC tumors 55 prospectively defined 55 IgG1 monoclonal antibody 55 Rituxan rituximab 55 BRAF V# mutation 55 Metastatic Breast Cancer 55 Tavocept 55 Brentuximab Vedotin SGN 55 pegylated interferon alpha 55 anthracycline taxane 55 Stimuvax 55 luteinizing hormone releasing 55 previously untreated follicular 55 Arranon 55 Satraplatin 55 tumor histology 55 cetuximab Erbitux ® 55 docetaxel Taxotere 55 secondary hyperparathyroidism 55 satraplatin 55 lung cancer 55 sorafenib tablets 55 allogeneic SCT 55 anaplastic lymphoma kinase 55 melphalan prednisone 55 tumor subtypes 55 VIDAZA 55 Taxotere 55 cholangiocarcinoma 55 SHPT 55 phase IIb trial 55 premalignant 55 metastatic pancreatic 55 gastrointestinal cancers 55 goserelin 55 ZYBRESTAT 55 pegylated liposomal doxorubicin PLD 55 Voreloxin 55 sunitinib Sutent 55 cutaneous squamous cell carcinoma 55 locoregional recurrence 55 dose escalation clinical 55 oral ridaforolimus 55 cisplatin resistant 55 talactoferrin 55 BARACLUDE ® 55 FOLFOX regimen 55 nodular BCC 55 Xyotax 55 metastatic squamous cell carcinoma 55 therapeutic regimens 55 alemtuzumab 55 Tarceva TM 55 standard chemotherapy regimen 55 myeloma 55 OMAPRO 55 Kahalalide F 55 Cotara 55 thalidomide Thalomid 55 liver metastasis 55 refractory 55 TACE 55 mesotheliomas 55 Phase Ib clinical 55 TTF Therapy 55 T1a 55 cytokine refractory 55 HBeAg positive 55 interferon IFN 55 cell lymphoma 55 Zolinza 55 sarcoma 55 ALCL 55 Hycamtin 55 CANCIDAS 55 splenectomized patients 55 pCR 55 Onrigin 55 leukaemias 55 CD# antibody [001] 55 eribulin 55 Enzastaurin 55 neratinib 55 CA4P 55 oblimersen 55 Epidermal Growth Factor Receptor 55 familial amyloidotic polyneuropathy FAP 55 BRAF V#E mutation 55 custirsen 55 AA amyloidosis 55 trastuzumab DM1 55 lung carcinomas 55 elesclomol 55 Erbitux cetuximab 54 neovascular AMD 54 ToGA 54 EGFR gene 54 PLX# 54 ER CHOP 54 tyrosine kinase inhibitor TKI 54 Randomized Phase II 54 tumor regression 54 GRN#L 54 Lenalidomide 54 Triapine 54 FOLFIRINOX 54 refractory APL 54 Telintra 54 skeletal metastases 54 dose cohort 54 Evoltra ® 54 advanced metastatic prostate 54 Alessandro Riva 54 dose escalation Phase 54 interferon therapy 54 gastric adenocarcinoma 54 grade cervical intraepithelial 54 COPD 54 TroVax ® 54 HCV infections 54 Myelodysplastic Syndromes 54 EFAPROXYN 54 transthyretin amyloidosis 54 visceral metastases 54 micrometastases 54 cabazitaxel 54 XYOTAX TM 54 gastric carcinoma 54 Phase 2b study 54 MGUS 54 metastatic colorectal carcinoma 54 samalizumab 54 invasive aspergillosis 54 Bevacizumab 54 Cloretazine R 54 cytoreduction 54 PSADT 54 Rituximab 54 biliary cancer 54 activating EGFR mutations 54 cytoreductive nephrectomy 54 IMC #B 54 relapsing MS 54 colorectal tumors 54 premalignant lesions 54 Glioblastoma Multiforme GBM 54 DMARD therapy 54 nucleoside analogue 54 recurrent prostate cancer 54 IL# PE#QQR 54 milatuzumab 54 prostate cancer 54 palliative radiotherapy 54 hormonal therapies 54 Atypical Hemolytic Uremic Syndrome 54 thromboembolic events 54 haematologic malignancies 54 Sutent sunitinib 54 bosutinib 54 REVLIMID 54 APPRAISE 54 PF # [001] 54 ECOG 54 breast cancer subtypes 54 non Hodgkin lymphoma 54 CBLC# 54 antibody MAb 54 Troxatyl 54 histologic subtype 54 lobular carcinoma 54 fallopian tube cancers 54 malignant melanoma 54 Soft Tissue Sarcoma 54 ADPKD 54 hemodialysis patients 54 cytologically confirmed 54 MGCD# [001] 54 randomized Phase 2b 54 Sutent 54 Nexavar 54 Interferon alfa 54 Phase 2b trial 54 pralatrexate 54 INGN 54 BRCA mutation carriers 54 picoplatin 54 HCV RESPOND 2 54 hA# 54 PKC# 54 ALN TTR 54 nonmetastatic prostate cancer 54 GBM tumors 54 dose escalation 54 bortezomib Velcade 54 chronic lymphocytic leukemia 54 TACI Ig 54 virologic failure 54 pain palliation 54 evaluable subjects 54 cystectomy 54 romidepsin 54 K RAS 54 essential thrombocythemia 54 Phase 2a trial 54 colorectal carcinomas 54 Taxotere R 54 ZEVALIN 54 Malignant Melanoma 54 INCB# [002] 54 anti VEGF 54 Zevalin consolidation 54 Papillary 54 TELCYTA 54 basal cell carcinomas 54 Median survival 54 Zybrestat 54 lung pancreatic 54 HCV genotypes 54 Acute Coronary Syndromes ACS 54 abiraterone 54 mTOR inhibitor 54 valopicitabine 54 relapsed Hodgkin lymphoma 54 Myelodysplastic syndromes MDS 54 hormone deprivation 54 dirucotide 54 Myelodysplastic Syndrome 54 adriamycin 54 nasopharyngeal cancer 54 CanAg 54 EGFR activating mutations 54 antitumor effect 54 thymalfasin 54 satraplatin Phase 54 Sorafenib 54 registrational 54 NSABP B